These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide. Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977 [TBL] [Abstract][Full Text] [Related]
7. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. Hu J; Jo M; Cavenee WK; Furnari F; VandenBerg SR; Gonias SL Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15984-9. PubMed ID: 21896743 [TBL] [Abstract][Full Text] [Related]
8. Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR. Vaidya KS; Mitten MJ; Zelaya-Lazo AL; Oleksijew A; Alvey C; Falls HD; Mishra S; Palma J; Ansell P; Phillips AC; Reilly EB; Anderson M; Boghaert ER J Neurooncol; 2021 Apr; 152(2):233-243. PubMed ID: 33517558 [TBL] [Abstract][Full Text] [Related]
9. EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma. Li L; Puliyappadamba VT; Chakraborty S; Rehman A; Vemireddy V; Saha D; Souza RF; Hatanpaa KJ; Koduru P; Burma S; Boothman DA; Habib AA Oncogene; 2015 Jan; 34(1):129-134. PubMed ID: 24362532 [TBL] [Abstract][Full Text] [Related]
10. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063 [TBL] [Abstract][Full Text] [Related]
11. Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation. Grogan PT; Sarkaria JN; Timmermann BN; Cohen MS Invest New Drugs; 2014 Aug; 32(4):604-17. PubMed ID: 24718901 [TBL] [Abstract][Full Text] [Related]
12. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo. Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701 [TBL] [Abstract][Full Text] [Related]
13. EGFRvIII Promotes the Proneural-Mesenchymal Transition of Glioblastoma Multiforme and Reduces Its Sensitivity to Temozolomide by Regulating the NF-κB/ALDH1A3 Axis. Shi ZF; Li GZ; Zhai Y; Pan CQ; Wang D; Yu MC; Liu C; Zhang W; Yu XG Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980923 [TBL] [Abstract][Full Text] [Related]
14. Proteomic analysis of the epidermal growth factor receptor (EGFR) interactome and post-translational modifications associated with receptor endocytosis in response to EGF and stress. Tong J; Taylor P; Moran MF Mol Cell Proteomics; 2014 Jul; 13(7):1644-58. PubMed ID: 24797263 [TBL] [Abstract][Full Text] [Related]
15. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status. Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314 [TBL] [Abstract][Full Text] [Related]
18. Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line. Nishimura Y; Yoshioka K; Bereczky B; Itoh K Mol Cancer; 2008 May; 7():42. PubMed ID: 18492291 [TBL] [Abstract][Full Text] [Related]
19. The epidermal growth factor receptor variant type III mutation frequently found in gliomas induces astrogenesis in human cerebral organoids. Kim HM; Lee SH; Lim J; Yoo J; Hwang DY Cell Prolif; 2021 Feb; 54(2):e12965. PubMed ID: 33283409 [TBL] [Abstract][Full Text] [Related]
20. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma. Zheng Q; Han L; Dong Y; Tian J; Huang W; Liu Z; Jia X; Jiang T; Zhang J; Li X; Kang C; Ren H Neuro Oncol; 2014 Sep; 16(9):1229-43. PubMed ID: 24861878 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]